Fate has a devoted management team with the experience and track record to explore new biology, develop innovative therapeutics, create formidable intellectual property, launch new business models and foster strategic collaborations.

WILLIAM RASTETTER, PH.D. CEO In addition to his role as chairman and CEO at Fate, Bill also currently serves as Chairman of the Board at Receptos, Illumina and Neurocrine Biosciences. Bill is a partner at Venrock, which he joined in 2006 from Biogen Idec, where he was most recently executive chairman. Bill joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion-dollar market valuation company, while serving as Chairman and CEO. He was at Biogen Idec from the merger of the two companies in 2003, through the end of 2005. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and also served in a scientific capacity at the company. Adding to his corporate background, Bill held various faculty positions at MIT, won the award for “Excellence in the Teaching of Chemistry” at Harvard and is an Alfred P. Sloan Fellow. He is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering, and biotechnology. Bill holds a B.S. in chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in chemistry from Harvard University.	PRATIK MULTANI, M.D., M.S. Senior Vice President of Clinical Development Dr. Multani is the senior vice president of clinical development at Fate Therapeutics. Prior to joining Fate Therapeutics, Dr. Multani had been vice president of translational medicine at Kalypsys, Inc. since 2007, where he advanced the development of multiple compounds in the therapeutic areas of pain and inflammation and metabolic diseases. From 2005 to 2007 as senior vice president of clinical development and then chief medical officer at Kanisa Pharmaceuticals, Dr. Multani led the clinical development of zosuquidar as well as a companion diagnostic for the treatment of acute myeloid leukemia. From 2004 to 2005 as vice president of clinical development at Salmedix, he led three clinical development programs in hematologic malignancies and solid tumors. From 1999 to 2004 advancing from associate director of oncology and hematology to senior director of medical research at Biogen-Idec, Dr. Multani led or provided strategic direction for multiple drug development programs from pre-IND to Phase 4 clinical trials, including Zevalin® and Rituxan. Pratik received his undergraduate degree from Yale University, his MD from Harvard Medical School and received post-doctoral training in epidemiology at the Harvard School of Public Health. He completed his Internal Medicine residency at the Massachusetts General Hospital followed by a medical oncology fellowship at the Dana Farber/Partners joint program, after which he was a member of the transplant unit at Massachusetts General Hospital.
DAN SHOEMAKER, PH.D. Chief Technology Officer Dr. Shoemaker is Fate’s chief technology officer and is leading the company’s drug discovery efforts. Dr. Shoemaker was previously chief scientific officer of ICxBiosystems, which develops advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. He led the technology team in establishing molecular tools to enrich and analyze rare cell populations. From 2003 to 2005, he was chief scientific officer of GHC Technologies and led the research and development of rapid ultrasensitive detection assays for biodefense and clinical point-of-care diagnostics. From 1998 to 2003, Dr. Shoemaker held several positions at Merck Research Laboratories, including director of Target Discovery, senior director at Rosetta Inpharmatics and research fellow in the Department of Molecular Neurosciences, where his main focus was on target identification and biomarker discovery. Dr. Shoemaker’s research at Merck achieved publications in top journals, including Nature, Science and Nature Biotechnology. Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from University of California, Santa Barbara.	SCOTT WOLCHKO Chief Financial Officer and Vice President of Operations Mr. Wolchko is the chief financial officer of Fate Therapeutics and is responsible for financial, business development, intellectual property and administration activities. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of the firm’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the chief financial officer of Bocada, Inc., where he oversaw all corporate service-related operations, and was previously the senior director of corporate development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.
PETER FLYNN, PH.D. Vice President, Biologics Therapeutics Dr. Flynn is the vice president of biologic therapeutics and iPSC technology at Fate Therapeutics. He manages the in vivo protein therapeutics pipeline and preclinical development and the iPSC technology group, including the collaboration with Becton Dickinson (BD). Peter has been involved in biotechnology start-ups with a focus on biologic therapeutics for over ten years. Prior to joining Fate Therapeutics, he was Vice President of Research for Ren Pharmaceuticals, where he led the R&D effort to identify biologic therapeutics to treat renal disease and hypertension. Prior to Ren, Peter was Director of Biochemistry Research at KaloBios Pharmaceuticals, an antibody therapeutics company. Peter was a member of the KaloBios team from incorporation and was integral in the development of the platform antibody HumaneeringTM technology. Peter played a major role in the identification and preclinical development of KaloBios’ three initial therapeutic antibodies for the treatment of infectious disease, inflammation and cancer. Prior to the formation of KaloBios, Peter was a researcher at UCSF Comprehensive Cancer Center. He gained a PhD from the ICRF London (Cancer Research UK) and a BSc in molecular biology from University College London. He is the author of many publications and patents in the areas of cellular signal transduction, antibody engineering and induced pluripotency.	ZACHARY HORNBY, MBA, M.S. Senior Director of Business Development Mr. Hornby is the senior director of business development at Fate Therapeutics and has served in multiple commercial functions within the biotech industry over the past ten years. Prior to joining Fate, Mr. Hornby was director of business development at Halozyme Therapeutics where he participated on multiple in-licensing and out-licensing transactions and was responsible for managing the company’s portfolio of academic licenses. Prior to Halozyme, Mr. Hornby served as a senior product manager at Neurocrine Biosciences, where he gained market development and new product planning experience. Earlier in his career, Mr. Hornby held regulatory affairs and business development positions at Transkaryotic Therapies (TKT: now Shire Pharmaceuticals) and was a consultant at L.E.K. Consulting, focused exclusively on the life sciences industry. Mr. Hornby holds B.S. and M.S. degrees in biology from Stanford University and an MBA from Harvard Business School.
CINDY TAHL, J.D. Senior Director of Intellectual Property and Corporate Counsel Cindy Tahl is the senior director of intellectual property and corporate counsel at Fate Therapeutics. Ms. Tahl manages the company’s intellectual property and is responsible for building and maintaining a robust patent portfolio. Prior to joining Fate Therapeutics, Ms. Tahl was an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, P.C. As a member of the firm’s technology transactions group, she worked extensively with early stage biotechnology companies to implement strategies for the protection, management and licensing of intellectual property assets, and represented clients in corporate transactions relating to the acquisition, transfer and use of intellectual property rights. Earlier in her career, Ms. Tahl was an associate in the New York office of Kenyon & Kenyon, LLP, where she managed the patent portfolios of biotechnology and pharmaceutical companies, including preparing and prosecuting U.S. and PCT patent applications and directing prosecution of foreign counterparts and executing prosecution strategy. She also advised clients on the scope, infringement, validity and enforceability of U.S. patents, assisting in risk assessment, enforcement of IP rights and the defense of claims of infringement of third party IP rights. Ms. Tahl earned a J.D. from Boston College Law School and a B.S. in biology from the University of California, San Diego. She is admitted to the California and New York Bars, and is registered to practice as a patent attorney before the U.S. Patent and Trademark Office.	SCOTT THIES, PH.D. Senior Director of Stem Cell Biology Dr. Thies is the senior director of stem cell biology at Fate Therapeutics and has been working with stem cells and regenerative medicine in the biotech industry for 20 years. Most recently, he was the director of cell technology at Geron Corporation. There, he led the assay development effort to characterize cell therapeutics derived from embryonic stem cells, devised differentiation strategies for neural lineage cell therapeutics and played a pivotal role in filing an IND for the first embryonic stem cell-derived therapeutic. Prior to joining Geron, Dr. Thies was a senior scientist in Regenerative Medicine at Genetics Institute and, subsequently, at Wyeth Pharmaceuticals. His research there focused on members of the BMP family and included identifying novel receptors and developing proprietary assays for discovering the therapeutic potential of this protein family. Dr. Thies is an author on 30 papers and an inventor on eleven patents. He completed postdoctoral training in biological chemistry and endocrinology at the University of California, Los Angeles and the University of California, San Diego, respectively. Dr. Thies earned a Ph.D. in physiology from Duke University and a B.S. in biology and chemistry from the University of Miami.